Allarity reports Q3 EPS (19c) vs ($7.71) last year

“The third quarter of 2025 was another milestone period for Allarity (ALLR) as we achieved FDA Fast Track designation for stenoparib in advanced ovarian cancer-an important acknowledgment of the potential of our lead program. We also reported new clinical data showing median overall survival now exceeding 25 months for patients in our Phase 2 trial-a remarkable finding in this difficult-to-treat population. Alongside these achievements, we continued to advance our DRP platform commercially through a new licensing and laboratory services agreement,” said Thomas Jensen, CEO of Allarity Therapeutics. “The consistency of our progress reflects our disciplined, focused strategy and execution. Stenoparib continues to show durable clinical benefit in women with advanced, platinum resistant ovarian cancer, and we continue to deepen our understanding of its unique dual mechanism of action through our collaboration with the Indiana Biosciences Research Institute. With both the ongoing ovarian cancer trial progressing under Fast Track designation and the forthcoming U.S. Veterans Administration-funded small cell lung cancer combination study advancing toward initiation, we see the potential to broaden stenoparib’s therapeutic reach-offering new hope for patients across multiple hard-to-treat cancer types.”